Sara Nadworny

575 total citations
3 papers, 12 citations indexed

About

Sara Nadworny is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Sara Nadworny has authored 3 papers receiving a total of 12 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Oncology, 2 papers in Pulmonary and Respiratory Medicine and 2 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Sara Nadworny's work include Lung Cancer Treatments and Mutations (2 papers), Cancer therapeutics and mechanisms (1 paper) and HER2/EGFR in Cancer Research (1 paper). Sara Nadworny is often cited by papers focused on Lung Cancer Treatments and Mutations (2 papers), Cancer therapeutics and mechanisms (1 paper) and HER2/EGFR in Cancer Research (1 paper). Sara Nadworny collaborates with scholars based in United States. Sara Nadworny's co-authors include Victor M. Rivera, John Hodgson, Scott Wardwell, Sen Zhang, Lindsey Eichinger, Adam C. Talbot, Hans K. Erickson, Xiuxia Sun, Peter U. Park and Min Li and has published in prestigious journals such as Cancer Research and Molecular Cancer Therapeutics.

In The Last Decade

Sara Nadworny

3 papers receiving 12 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sara Nadworny United States	2	11	10	5	1	1	3	12
J. Mazieres France	2	9 0.8×	8 0.8×	5 1.0×	1 1.0×		3	11
Ilias Kainis Greece	2	9 0.8×	6 0.6×	5 1.0×		1 1.0×	3	12
Rieke Frank Germany	2	16 1.5×	14 1.4×	4 0.8×		1 1.0×	3	19
Timothy Langford United States	3	9 0.8×	6 0.6×	7 1.4×	1 1.0×	1 1.0×	8	20
Viran Holden United States	2	15 1.4×	14 1.4×	3 0.6×	1 1.0×		2	18
Xiaohua Ou China	2	16 1.5×	17 1.7×	6 1.2×			2	19
Lucia Grillo Italy	2	7 0.6×	10 1.0×	9 1.8×			3	13
Amar Rahi United Kingdom	2	9 0.8×	8 0.8×	10 2.0×		1 1.0×	3	23
Anna Eisert Germany	2	10 0.9×	5 0.5×	4 0.8×		1 1.0×	11	10
Teresa Morán Bueno Spain	2	17 1.5×	18 1.8×	5 1.0×	1 1.0×	1 1.0×	2	19

Countries citing papers authored by Sara Nadworny

Since Specialization

Citations

This map shows the geographic impact of Sara Nadworny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Nadworny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Nadworny more than expected).

Fields of papers citing papers by Sara Nadworny

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Nadworny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Nadworny. The network helps show where Sara Nadworny may publish in the future.

Co-authorship network of co-authors of Sara Nadworny

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Nadworny. A scholar is included among the top collaborators of Sara Nadworny based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Nadworny. Sara Nadworny is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

3 of 3 papers shown

1.

Zhang, Sen, Sara Nadworny, Wei‐Sheng Huang, et al.. (2023). Abstract B167: Preclinical characterization of THE-349, a mutant-selective, CNS-active, fourth-generation EGFR inhibitor to overcome T790M- and C797S-mediated resistance in NSCLC. Molecular Cancer Therapeutics. 22(12_Supplement). B167–B167. 2 indexed citations

2.

Zhang, Sen, Sara Nadworny, Scott Wardwell, et al.. (2015). Abstract 781: The potent ALK inhibitor AP26113 can overcome mechanisms of resistance to first- and second-generation ALK TKIs in preclinical models. Cancer Research. 75(15_Supplement). 781–781. 9 indexed citations

3.

Lai, Katharine C., Hans K. Erickson, Xiuxia Sun, et al.. (2011). Abstract B209: The CD37-targeting ADC IMGN529 combines the potent anticancer activity of K7153A antibody with efficient maytansinoid delivery.. Molecular Cancer Therapeutics. 10(11_Supplement). B209–B209. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact